Waters upgraded by Evercore ISI with a new price target
$WAT
Biotechnology: Laboratory Analytical Instruments
Industrials
Evercore ISI upgraded Waters from In-line to Outperform and set a new price target of $350.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2026 | $425.00 | Outperform | Wolfe Research |
| 4/6/2026 | $350.00 | In-line → Outperform | Evercore ISI |
| 2/10/2026 | $360.00 | In-line | Evercore ISI |
| 2/10/2026 | $425.00 | Buy | Citigroup |
| 2/10/2026 | $400.00 | Overweight | Barclays |
| 1/6/2026 | $440.00 | Buy | Guggenheim |
| 1/5/2026 | Outperform | William Blair | |
| 12/10/2025 | $480.00 | Peer Perform → Outperform | Wolfe Research |
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
Wolfe Research resumed coverage of Waters with a rating of Outperform and set a new price target of $425.00
Evercore ISI upgraded Waters from In-line to Outperform and set a new price target of $350.00
Evercore ISI resumed coverage of Waters with a rating of In-line and set a new price target of $360.00
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics.Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.Fully automated solution delivers an industry-leading 50% increase in vial loading and up to 960-vial per module capacity, maximizing walk-away time.MILFORD, Mass., June 3, 2026 /CNW/ -- Waters Corporation (NYSE:WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in
Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows.Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.Sets a new benchmark for throughput in high-resolution spatial analysis with the DESI XS source, supporting higher-confidence studies of disease and treatment response.MILFORD, Mass., June 1, 2026 /CNW/ -- 74th ASMS Conference on Mass Spectrometry and Allied Topics—Waters Corporation (NYSE:WAT) today introduced the Waters Xevo™
>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals.50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics.Integrated MALDI XS and DESI XS imaging with high-resolution ion mobility enables direct visualization of molecules in tissue, improving understanding of how disease develops at the cellular level.MILFORD, Mass., June 1, 2026 /PRNewswire/ -- 74th ASMS Conference on Mass Spectrometry and Allied Topics— Waters Corporation (NYSE:WAT) today announced the launch of
SD - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
10-Q - WATERS CORP /DE/ (0001000697) (Filer)
Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies
MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
First Quarter 2026 HighlightsTotal reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acquired businesses.Organic revenue grew 13% as reported and 11% in constant currency, exceeding the high end of the constant currency growth guidance range by 200 basis points – led by high-single-digit instrument growth and mid-teens chemistry growth within the Analytical Sciences Division.The Biosciences and Diagnostic Solutions businesses generated $520 million of reported revenue since the closing of the acquisition – $40 million above guidance – driven by traction from commercial execution and o
MILFORD, Mass., April 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 2, 2026, at midnight Eastern Time. About Waters CorporationWaters Corporation (NYSE:WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innova
Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currencyGrowth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regionsChemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demandInstruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for EmpowerGAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digitsFull-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)